World-Class Lung Cancer Treatment in Shanghai
Lung cancer is the leading cause of cancer death worldwide, accounting for more deaths than breast, colon, and prostate cancers combined. Yet the past decade has seen a revolution in lung cancer treatment — driven by targeted therapies for driver mutations and immunotherapy — that has transformed outcomes for many patients. For international patients seeking the most advanced lung cancer care, Shanghai's Chest Hospital is home to one of the world's most cited and influential lung cancer specialists.
Featured Specialist: Prof. Lu Shun
Prof. Lu Shun is a leading medical oncologist at Shanghai Chest Hospital (Shanghai Shi Xiongke Yiyuan) — China's premier dedicated thoracic disease center and one of Asia's most respected institutions for lung cancer diagnosis and treatment.
Prof. Lu's international standing is exceptional:
- Global Highly Cited Scientist — recognized by Clarivate Analytics among the world's most influential researchers in clinical medicine, placing him in the top 1% of cited scientists globally
- State Council Special Allowance Expert (国务院特殊津贴专家) — China's highest government recognition for outstanding scientific contribution
- Principal investigator on a large number of domestic and international clinical trials, including pivotal studies that led to the approval of domestically developed targeted therapies in China
- His research has directly contributed to significantly improved survival rates for advanced EGFR-mutated lung cancer patients
Understanding Lung Cancer: Why Molecular Testing Matters
Modern lung cancer treatment begins with comprehensive molecular profiling of the tumor. The treatment approach — and the likelihood of response — depends critically on which genetic driver, if any, is present:
- EGFR mutation (most common in Asian non-smokers, ~50% of Asian adenocarcinoma): Highly responsive to EGFR tyrosine kinase inhibitors (TKIs)
- ALK rearrangement (~5%): Responds dramatically to ALK inhibitors (crizotinib, alectinib, lorlatinib)
- ROS1 rearrangement (~2%): Responds to ROS1 inhibitors
- KRAS G12C mutation: Now targetable with sotorasib and adagrasib
- MET exon 14 skipping: Responds to MET inhibitors (tepotinib, capmatinib)
- RET fusion, BRAF V600E, HER2 mutation: Each with dedicated targeted agents
- No driver mutation (wild-type): Immunotherapy (PD-1/PD-L1 inhibitors) ± chemotherapy is the primary approach
EGFR-Mutated Lung Cancer: Prof. Lu's Area of Global Leadership
Prof. Lu has been at the forefront of EGFR-targeted therapy research for over two decades. His clinical and research contributions span the full evolution of EGFR treatment:
First-Generation EGFR TKIs
- Gefitinib, erlotinib — established the proof of concept for EGFR-targeted therapy
Second-Generation EGFR TKIs
- Afatinib, dacomitinib — improved progression-free survival over first-generation agents
Third-Generation EGFR TKIs
- Osimertinib (Tagrisso) — current standard of care for first-line EGFR+ NSCLC and T790M resistance mutation; superior CNS penetration for brain metastases
- Aumolertinib and furmonertinib — domestically developed third-generation TKIs whose approval Prof. Lu's research helped advance, offering Chinese patients access to effective alternatives
Post-Progression Strategies
- Re-biopsy and liquid biopsy (ctDNA) to identify resistance mechanisms
- Combination strategies for T790M-negative resistance (chemotherapy, anti-angiogenic agents, immunotherapy combinations)
- Emerging fourth-generation EGFR inhibitors for C797S resistance mutation
- EGFR-targeted antibody-drug conjugates (patritumab deruxtecan)
Immunotherapy for Lung Cancer
For patients without a targetable driver mutation, immunotherapy has transformed the treatment landscape. Prof. Lu's expertise in lung cancer immunotherapy includes:
- PD-1/PD-L1 inhibitors as first-line monotherapy for high PD-L1 expressors (TPS ≥50%)
- Chemo-immunotherapy combinations for patients with lower PD-L1 expression
- Dual immunotherapy (nivolumab + ipilimumab) for selected patients
- Biomarker-guided selection — PD-L1 testing, TMB (tumor mutational burden), and STK11/KEAP1 mutation status to predict immunotherapy response
- Immunotherapy in special populations — elderly patients, poor performance status, autoimmune comorbidities
Clinical Trial Access at Shanghai Chest Hospital
As one of China's most active lung cancer clinical researchers, Prof. Lu offers patients access to trials of novel agents that are not yet commercially available, including:
- Next-generation EGFR inhibitors for resistant disease
- Novel immunotherapy combinations and bispecific antibodies
- KRAS G12C inhibitor combinations
- Antibody-drug conjugates for lung cancer
- Biomarker-selected basket trials for rare driver mutations
About Shanghai Chest Hospital
Shanghai Chest Hospital is China's premier dedicated thoracic disease center, affiliated with Shanghai Jiao Tong University School of Medicine. It is nationally designated as a key center for lung cancer, esophageal cancer, and thoracic surgery, and operates one of China's largest lung cancer multidisciplinary tumor boards. Its concentration of thoracic expertise — medical oncology, thoracic surgery, radiation oncology, interventional pulmonology, and pathology — under one roof makes it uniquely suited for complex lung cancer cases.
How CMCS Coordinates Your Care
China Medical Concierge Shanghai (CMCS) is a health management company — not a hospital. We connect international patients with Shanghai's leading lung cancer specialists, including Prof. Lu Shun at Shanghai Chest Hospital, and manage every step of the process:
- Review of existing pathology, molecular profiling (NGS panel), and imaging
- Coordination of additional molecular testing if needed (EGFR, ALK, ROS1, KRAS, MET, RET, PD-L1, TMB)
- Clinical trial eligibility screening based on Prof. Lu's current trial portfolio
- Appointment scheduling with priority access
- Medical interpretation during consultations and tumor board discussions
- Logistics support: accommodation, visa assistance, and local transport
- Post-consultation follow-up and remote monitoring coordination
Get in Touch
If you or a family member has been diagnosed with lung cancer and are exploring treatment options in Shanghai, contact our team for a confidential consultation.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
0 commentaire